

1 SARS-CoV-2 transmission in intercollegiate athletics 2 not fully mitigated with daily antigen testing

3 Gage K. Moreno^{1*}, Katarina M. Braun^{2*}, Ian W. Pray^{3,4}, Hannah E. Segaloff^{3,4}, Ailam Lim⁵, Keith
4 Poulson⁵, Jonathan Meiman³, James Borcher⁶, Ryan P. Westergaard^{3,7}, Michael K. Moll⁸,
5 Thomas C. Friedrich², David H. O'Connor¹

6 * These authors contributed equally

7 ¹ Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison USA
8 53711

9 ² Department of Pathobiological Sciences, University of Wisconsin-Madison USA 53711

10 ³ Wisconsin Department of Health Services, USA 53703

11 ⁴ Epidemic Intelligence Service, Centers for Disease Control and Prevention USA 30333

12 ⁵ Wisconsin Veterinary Diagnostic Laboratory, University of Wisconsin-Madison USA 53711

13 ⁶ Department of Family Medicine, Division of Sports Medicine, Ohio State University
14 USA 43210

15 ⁷ Department of Medicine, University of Wisconsin-Madison, USA 53711

16 ⁸ Athletic Department, University of Wisconsin-Madison USA 53711

17 **Running title** (40 characters or less): SARS-CoV-2 in intercollegiate athletics

18 **Corresponding author contact information:** David O'Connor, email: dhoconno@wisc.edu

19 **Keywords** (up to 5): SARS-CoV-2, antigen testing,

20 **Summary** (40 words or less): High frequency, rapid turnaround SARS-CoV-2 testing continues

21 to be proposed as a way of efficiently identifying and mitigating transmission in congregate

22 settings. However, here we describe two SARS-CoV-2 outbreaks occurred among

23 intercollegiate university athletic programs during the fall 2020 semester.

24

25 Abstract

26 Background

27 High frequency, rapid turnaround SARS-CoV-2 testing continues to be proposed as a way of

28 efficiently identifying and mitigating transmission in congregate settings. However, two SARS-

29 CoV-2 outbreaks occurred among intercollegiate university athletic programs during the fall

30 2020 semester despite mandatory directly observed daily antigen testing.

31 Methods

32 During the fall 2020 semester, athletes and staff in both programs were tested daily using

33 Quidel's Sofia SARS Antigen Fluorescent Immunoassay (FIA), with positive antigen results

34 requiring confirmatory testing with real-time reverse transcription polymerase chain reaction

35 (RT-PCR). We used genomic sequencing to investigate transmission dynamics in these two

36 outbreaks.

37 Results

38 In Outbreak 1, 32 confirmed cases occurred within a university athletics program after the index
39 patient attended a meeting while infectious despite a negative antigen test on the day of the
40 meeting. Among isolates sequenced from Outbreak 1, 24 (92%) of 26 were closely related,
41 suggesting sustained transmission following an initial introduction event. In Outbreak 2, 12
42 confirmed cases occurred among athletes from two university programs that faced each other in
43 an athletic competition despite receiving negative antigen test results on the day of the
44 competition. Sequences from both teams were closely related and unique from strains
45 circulating in the community, suggesting transmission during intercollegiate competition.

46 Conclusions

47 These findings suggest that antigen testing alone, even when mandated and directly observed,
48 may not be sufficient as an intervention to prevent SARS-CoV-2 outbreaks in congregate
49 settings, and highlights the importance of supplementing serial antigen testing with appropriate
50 mitigation strategies to prevent SARS-CoV-2 outbreak in congregate settings.

51 Introduction

52 Timely reporting of SARS-CoV-2 test results is critical for controlling transmission through
53 prompt public health action, yet at times during 2020, turnaround times for SARS-CoV-2 test
54 results in the United States have averaged 4 days, with some individuals waiting 10 days or
55 more [1]. While turnaround times in early 2021 have improved, the lag between specimen
56 collection and receipt of a test result continues to represent a window in which the risk of viral
57 spread from SARS-CoV-2-infected individuals is high. Rapid antigen tests, like Abbott's

58 BinaxNow COVID-19 Ag Card and Quidel's Sofia SARS Antigen FIA, can reduce this lag
59 between testing and results reporting [2–5]. Because of these qualities, high-frequency, rapid
60 turnaround SARS-CoV-2 antigen testing has been proposed as a prevention strategy in many
61 congregate settings where SARS-CoV-2 infection risk is elevated [6–8].

62
63 In data submitted for emergency use authorization, the Sofia SARS Antigen FIA antigen test
64 reported a sensitivity of 97% and specificity of 100% when used for symptomatic patients within
65 five days of symptom onset [9,10]. It therefore follows that serial antigen testing could rapidly
66 identify persons with symptomatic infections enabling rapid isolation of such individuals [2,4].
67 Recent studies, however, have found that Sofia SARS Antigen FIA antigen was less sensitive
68 (41.2% sensitivity) when individuals were asymptomatic [10–13]. Use of Sofia SARS Antigen
69 FIA on asymptomatic patients is not included in the FDA authorization and is considered an “off-
70 label” use of the test. Nonetheless, many universities and other congregate settings have used
71 the tests for asymptomatic screening. The potential for false-negative antigen results among
72 asymptomatic patients may present a significant risk in that a negative test could result in risk
73 disinhibition behavior in a patient who may be infectious during their pre-symptomatic period,
74 which could lead to sustained and increased viral spread[14] (**Figure 1**).

75 Methods

76 A university implemented daily SARS-CoV-2 antigen testing for college
77 athletics

78 The two outbreaks occurred among athletes and staff affiliated with a university's intercollegiate
79 athletics programs despite daily SARS-CoV-2 testing with Quidel's Sofia SARS Antigen FIA.

80 Both sports involved in the outbreaks were considered “high-risk” by the national collegiate
81 athletics association (NCAA) due to frequent contact and collision between athletes during play.
82 Students and staff affiliated with the two athletics programs began daily antigen testing for
83 SARS-CoV-2 in September 2020. Daily antigen testing was not required for persons with a RT-
84 PCR-confirmed SARS-CoV-2 infection in the past 3 months, and persons experiencing
85 symptoms consistent with COVID-19, as symptomatic persons received RT-PCR testing without
86 initial antigen testing. For remaining asymptomatic students and staff, antigen testing was
87 conducted using anterior nasal swabs that were self-collected each morning under the direct
88 supervision of a nurse. Antigen test results were provided to athletics department medical staff
89 who coordinated exclusion from team activities and confirmatory testing, but were not reported
90 back to students and staff.

91
92 A negative antigen result meant an individual could engage in all sport-related activities, like
93 indoor meetings, practices, scrimmages, and intercollegiate competitions. Athletes and staff with
94 positive antigen results were immediately excluded from team activities by department medical
95 staff and subject to confirmatory testing with RT-PCR using the TaqPath COVID-19 Combo Kit
96 (Thermo Fisher Scientific). Students and staff with positive RT-PCR results were excluded from
97 team activities for 21 days and were interviewed by university staff to identify close contacts.
98 Close contacts of RT-PCR-confirmed students or staff were required to self-quarantine for 14
99 days from the date of last contact per public health guidance [17]. Importantly, contact tracing
100 for student athletes did not include contacts that occurred during practices, competitions,
101 meetings, or other team activities, but could include contacts that occurred during social
102 activities or at home (e.g., roommates). In addition to daily antigen testing, the athletic
103 programs implemented a physical distancing policy requiring all students and staff to be at least
104 six feet apart during meetings, and mandatory mask use during team activities.

105 Epidemiological investigation

106 Confirmed cases of COVID-19 were defined as students or staff affiliated with the two athletics
107 programs who received a positive SARS-CoV-2 RT-PCR result during the outbreak period.
108 False negative antigen results were defined as a negative antigen test result and a positive RT-
109 PCR result that were collected on the same day. During each outbreak, once the number of
110 confirmed cases reached the threshold established by intercollegiate athletics conference
111 protocols, in-person team activities were suspended, and all students and staff were tested with
112 RT-PCR. Specimens that tested positive by RT-PCR confirmation were used for sequencing
113 analysis.

114 The names of universities, the specific sports, and relevant dates have been removed from the
115 report to protect the privacy of the students and staff involved. We used identifiers (Athletics-##)
116 to denote individuals associated with these outbreaks. Dates are encoded as X-day-YY, 'X'
117 indicates the outbreak investigated, and 'YY' indicates the day of that outbreak. The first notable
118 event for each outbreak is "day 0" – in Outbreak 1, this was a negative antigen test for the index
119 case (who later tested positive by RT-PCR), and in Outbreak 2, this was the date of the first
120 competition between the two teams. This activity was reviewed by CDC and was conducted in a
121 manner consistent with applicable federal law and CDC policy¹.

122 Laboratory Methods

123 We obtained a waiver of HIPAA Authorization and were approved to obtain the clinical samples
124 along with a Limited Data Set by the Western Institutional Review Board (WIRB #1-1290953-1).
125 Sequences for this study were derived from 36 total nasopharyngeal (NP) swab samples
126 collected from Outbreak 1 (n=32) and Outbreak 2 hosting team (n=5), as well as the visiting
127 team's samples in Outbreak 2 (n=5).

128 Outbreak 1 viral RNA isolation

129 Nasal swabs were collected and placed in 3mL phosphate buffered saline. RNA was extracted
130 from 190 μ L of sample using the MagMAX™ Viral/Pathogen II (MVP II) Nucleic Acid Isolation Kit
131 (Thermo Fisher Scientific, Waltham, MA) and eluted in a volume of 50 μ L according to
132 manufacturer's instructions. 5 μ L of RNA was quantitated using a one-step RT-PCR using a
133 TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific).

134 Outbreak 2 viral RNA isolation

135 Nasopharyngeal swabs were received in 3mL of transport medium (VTM). Viral RNA (vRNA)
136 was extracted from 100 μ L of VTM using the Viral Total Nucleic Acid Purification kit (Promega,
137 Madison, WI, USA) on a Maxwell RSC 48 instrument, using manufacturer guidelines, and was
138 eluted in 50 μ L of nuclease free H₂O.

139 Complementary DNA (cDNA) generation

140 Complementary DNA (cDNA) was synthesized using a modified ARTIC Network approach[15].
141 Briefly, vRNA was reverse transcribed with SuperScript IV Reverse Transcriptase (Invitrogen,
142 Carlsbad, CA, USA) using random hexamers and dNTPs, according to manufacturer's
143 guidelines.

144 Multiplex PCR to generate SARS-CoV-2 genomes

145 SARS-CoV-2-specific multiplex PCR for nanopore sequencing was performed, similar to
146 amplicon-based approaches as previously described[15,16]. In short, primers for 96 overlapping
147 amplicons spanning the entire genome with amplicon lengths of 500 bp and overlapping by 75
148 to 100 bp between the different amplicons were used to generate cDNA. cDNA (2.5 μ L) was

149 amplified in two multiplexed PCR reactions. Following amplification, samples were pooled
150 together before ONT library preparation.

151 Library preparation and sequencing

152 A total of 5ng for each sample was made compatible for deep sequencing using the one-pot
153 native ligation protocol with Oxford Nanopore kit SQK-LSK109 and its Native Barcodes (EXP-
154 NBD104 and EXP-NBD114)[15]. Up to 24 samples were pooled prior to being run on the
155 appropriate flow cell (FLO-MIN106) using the 72hr run script.

156 Processing raw ONT data

157 Sequencing data was processed using the ARTIC bioinformatics pipeline
158 (<https://github.com/artic-network/artic-ncov2019>)[17]. Consensus sequences were assembled
159 for samples with greater than 400x coverage. Samples were excluded from analysis if gaps in
160 the consensus sequence totaled $\geq 20\%$ of the genome. The entire ONT analysis pipeline is
161 available at <https://github.com/gagekmoreno/SARS-CoV-2-in-Southern-Wisconsin>.

162 Phylogenetic analysis

163 Phylogenetic analysis was completed using tools implemented in Nextstrain custom builds
164 (<https://github.com/nextstrain/ncov>)[18,19]. Time-resolved and divergence phylogenetic trees
165 were built using the standard Nextstrain tools and scripts[18,19]. We used custom python
166 scripts to filter and clean metadata. Sequences names were coded as OB#-T#-A#. Where OB
167 signifies the outbreak, T represents the team that the sequence came from, and A is the athlete
168 from which the sample that the sequence was derived originated.

169 Data availability

170 Source data after mapping to SARS-CoV-2 reference genome (Genbank: MN908947.3) have
171 been deposited in the Sequence Read Archive (SRA) under bioproject PRJNA614504.

172 Results

173 Outbreak 1: Cases can be linked to a single viral introduction

174 An athlete (Athletics-1) received a negative antigen test result the morning of day-0. Later that
175 day, Athletics-1 attended an indoor meeting with approximately 10 other student-athletes and
176 staff in which attendees reportedly sat six feet apart and wore masks at all times. The following
177 morning (day-1), Athletics-1 received a positive antigen test result followed by RT-PCR swab for
178 confirmation. The confirmatory RT-PCR result was positive with a Ct of 15.9 and the athlete
179 began experiencing symptoms by mid-afternoon of day-1. During day-3 through day-7, four
180 attendees of the initial day-0 meeting developed symptoms and received subsequent positive
181 RT-PCR results. Additionally, three roommates of Athletics-1 who did not attend the meeting
182 developed symptoms on day-4 and received positive RT-PCR results on day-4 and day-5. In-
183 person team activities were suspended on day-8 to prevent additional transmission.

184 Program-wide RT-PCR and antigen testing was conducted seven times throughout the outbreak
185 period (day-7, 10, 13-17, and 20). Mass RT-PCR testing identified 21 new SARS-CoV-2
186 infections among students and staff. Of these, 18 (86%) were negative on contemporaneous
187 rapid antigen tests. Among 11 positive antigen results obtained during mass testing, 4 (36%)
188 were confirmed with RT-PCR and 7 (64%) received negative RT-PCR results.

189 Overall, during Outbreak 1, 32 individuals (22 students and 10 staff) from the program had

190 laboratory-confirmed SARS-CoV-2 infections (**Figure 2a**). Of confirmed cases, 4 (13%) were
191 tested with RT-PCR because they were symptomatic, 7 (22%) were antigen-positive and
192 received RT-PCR confirmation, and 21 (66%) were positive during mass RT-PCR testing.
193 Contact tracing interviews found that 13 (40%) of 32 confirmed cases attended a team meeting
194 where someone with confirmed COVID-19 was present and in their infectious period; 6 (13%)
195 had close contact with a roommate with COVID-19; and 8 (25%) did not have any documented
196 exposures (**Table 1**).

197 To investigate the relationship among SARS-CoV-2 cases in outbreak 1, we generated
198 consensus sequences for 26 (81%) of 32 RT-PCR positive samples using the ARTIC Network
199 tiled amplicon approach on an Oxford Nanopore Technologies MinION [15,16]. Samples from
200 the remaining six RT-PCR test-positive individuals in Outbreak 1 were not available at the time
201 of sequencing and were excluded from this analysis. We found that 24 (92%) of these 26
202 genomic sequences cluster tightly in the Nextstrain 20A clade on a time-resolved tree and are
203 separated by 0-2 fixed consensus nucleotide differences (**Figure 3**). The limited diversity of
204 viruses detected in the 24 individuals suggests sustained transmission of SARS-CoV-2 following
205 a single introduction [20–22]. Viruses from Athletics-3 and Athletics-26 did not appear to be part
206 of the primary transmission cluster. As of 1-day-40, there was no evidence for onward spread
207 within the program originating from Athletics-3 or Athletics-26. The viruses infecting these
208 individuals cluster more closely with sequences seen in the community.

209 Outbreak 2: SARS-CoV-2 transmission during intercollegiate competition

210 Two teams from different universities engaged in intercollegiate competitions on consecutive
211 days (day-0 and day-1). Both teams underwent daily antigen testing and received all negative
212 antigen results in the week preceding the competitions, including both competition days (day-0

213 and day-1). No testing was conducted on day-2. On day-3, an athlete from Team 2 received a
214 positive antigen test result, which was confirmed by RT-PCR. No athletes or staff on either team
215 were quarantined from contact with the index athlete that occurred during competition on day-0
216 and day-1. During day-5 through day-10, multiple athletes on both teams developed symptoms
217 and received positive antigen and RT-PCR results. On day-6, all athletes on Team 1 were
218 tested by RT-PCR and in-person team activities were suspended. Overall, 12 athletes (seven
219 from Team 1 and five from Team 2) had confirmed SARS-CoV-2 infections during this outbreak
220 **(Figure 4)**.

221 To determine whether the source of these infections could be linked to competition despite
222 negative antigen results on the day of competition, we generated eight consensus sequences
223 from ten available samples. All eight virus sequences (four from each team) clustered tightly in
224 the 20G clade on a time-resolved tree and were separated by 0-2 fixed consensus nucleotide
225 differences **(Figure 4)**. Given the known epidemiological associations between these teams,
226 this likely represented a single transmission cluster [20–22].

227 The genetic sequences of the viruses infecting the individuals in Outbreak 2 were distinct from
228 the viruses circulating within the community where Outbreak 2 occurred. Moreover, sampling of
229 individuals in Outbreak 2 revealed a unique mutation, encoding Spike P26Y, that was present in
230 viral sequences from the samples from both teams but was not otherwise seen in the larger
231 community where Team 1 was located. Given the depth of surveillance community sequencing
232 in Team 1's community available during the outbreak period (~4.7% of test-positive cases), it is
233 unlikely that this unique signature arose independently in the community where Team 1 is
234 located.

235 Discussion

236 The SARS-CoV-2 testing strategy of daily, directly observed, rapid antigen testing implemented
237 by intercollegiate athletics programs nationwide has been resource-intensive, yet its impact on
238 SARS-CoV-2 transmission in this setting has not been evaluated. In this report, we described
239 two outbreaks within intercollegiate athletics programs in which daily antigen testing was unable
240 to interrupt SARS-CoV-2 transmission. In Outbreak 1, the index athlete received a positive RT-
241 PCR results with a low Ct value less than 24 hours after testing negative by the Sofia SARS
242 Antigen FIA. This individual was likely infectious on the date of the negative antigen test, as four
243 other individuals in the day-0 meeting contracted SARS-CoV-2 over the ensuing week.
244 Sustained transmission within the program followed when additional exposures from
245 presymptomatic and undetected SARS-CoV-2 infections occurred – at least 13 of the 32
246 outbreak-associated cases attended team meetings with individuals who had received negative
247 antigen results yet were in their infectious period.

248 Transmission within the program was not interrupted until the program implemented serial RT-
249 PCR testing, a strategy that led to identification of 21 new confirmed SARS-CoV-2 infections,
250 18 of which were negative on contemporaneous antigen tests. Our findings suggest that serial
251 antigen testing as a control strategy may have limited sensitivity for detecting early
252 asymptomatic infections, and that prevention of future outbreaks in these settings may require a
253 combination of more sensitive molecular tests (e.g., RT-PCR) and improved mitigation
254 measures.

255 Contact tracing during Outbreak 1 identified interactions between individuals that may have
256 contributed to at least 21 (66%) of the 32 confirmed cases (**Figure 2b**). These interactions
257 represent multiple breaches of the university's mitigation strategy and combined with the

258 limitations of the antigen testing protocol, resulted in sustained person-to-person viral spread
259 throughout the team. In particular, the team continued to have physically distanced (6 feet apart)
260 in-person meetings with cloth masks until all in-person team activities were suspended to
261 prevent further spread. Per public health and university guidelines, attendees in these meetings
262 were not quarantined, a step that may have prevented onward transmission during this
263 outbreak. Roommates and household contacts of student-athletes could represent additional
264 sources of infection in Outbreak 1. In some cases, housemates of infected team members were
265 not required to quarantine due to the large size of the house and the university's assessment
266 that physical distancing was achievable in this area. Continuing indoor in-person meetings and
267 not quarantining potential contacts represent possible breaches in university's SARS-CoV-2
268 mitigation plan that, combined with the limitation of antigen testing, permitted viral spread
269 throughout the team in Outbreak 1.

270 In Outbreak 2, we used genomic sequencing to demonstrate that SARS-CoV-2 transmission
271 likely occurred between two teams during athletic competition despite both teams receiving
272 negative antigen results prior to competition. Supporting evidence for inter-collegiate
273 transmission included detection of a unique mutation, Spike P26Y, that was common to the
274 samples from both teams but not otherwise seen in the community where Team 1 is located.
275 Given these findings, the most parsimonious explanation is that an infection acquired in the
276 community by the index athlete on Team 2 was transmitted to other individuals on both teams
277 during the time of competition.

278 The potential for inter-collegiate transmission during an athletic competition has important
279 implications for SARS-CoV-2 serial testing strategies and in-competition mitigation protocols.
280 First, antigen testing on the competition dates failed to identify the index case, who may have
281 been infectious and exposed other athletes. Like Outbreak 1, more sensitive molecular tests

282 may have identified the source case and allowed for exclusion from the competition. Second,
283 this investigation shows that athletic competition may pose a risk for SARS-CoV-2 transmission,
284 particularly in sports where direct physical contact occurs. This outbreak occurred during an
285 athletic competition that included contact and collision, and is considered “high-risk” by NCAA.
286 Despite the short duration of contact between athletes, transmission risk can be exacerbated
287 by heavy breathing and shouting without masking, which regularly occurs in this sport and has
288 been associated with SARS-CoV-2 outbreaks in other athletics competitions [30].

289 The findings in this report are subject to several limitations. First, we were not able to perform
290 genomic sequencing on all positive samples from these outbreaks (34 of 44 samples were
291 sequenced) either because of high Ct values on RT-PCR or lack of sample availability. Second,
292 contemporaneous antigen and RT-PCR samples in Outbreak 1 were not collected as “paired”
293 swabs (simultaneous swabbing of two nares) and may not be comparable to other antigen test
294 evaluations. Similarly, the performance of antigen tests in this context of daily serial testing
295 measured their ability to identify early presymptomatic infections, and may not be generalizable
296 to antigen test performance in other settings. Third, our ability to determine the source of
297 infections in these outbreaks was limited by incomplete contact tracing data. Undocumented
298 exposures between athletes and staff may have occurred outside of organized team activities
299 that could have caused infections that were attributed to team meetings or in-competition
300 transmission; although the strength of genomic clustering and epidemiologic evidence from
301 these investigations suggests that such occurrences were rare.

302 Among athletics programs and other congregate settings where outbreaks may spread rapidly
303 after introduction of SARS-CoV-2, serial antigen testing alone may not be sufficient to prevent
304 outbreaks. A robust testing strategy should be supplemented with multilayered prevention
305 strategies that includes correct and consistent mask use, physical distancing, increased hand

306 hygiene and disinfection, avoiding crowds and poorly ventilated spaces, and isolation of
307 symptomatic individuals regardless of antigen test result[13,23–25]. Serial testing with RT-PCR
308 may identify additional cases that were not detected by antigen testing, but the increased
309 sensitivity would have to be balanced with laboratory resources and increased turnaround
310 times.

311 Funding

312 This work was supported by COVID-19 Response grant from the Wisconsin Partnership
313 Program at the University of Wisconsin School of Medicine and Public Health to TCF and DHO.
314 GKM is supported by an NLM training grant to the Computation and Informatics in Biology and
315 Medicine Training Program (NLM 5T15LM007359).

316 Acknowledgments

317 We gratefully acknowledge Dr. Trevor Bedford and the entire Nextstrain team for making
318 Nextstrain phylogenetic tools publicly available and for their commitment to tracking the global
319 spread of SARS-CoV-2. We also acknowledge the GISAID team for maintaining the largest
320 public repository of SARS-CoV-2 sequence- and metadata.

321 Disclosures

322 The findings and conclusions in this report are those of the authors and do not necessarily
323 represent the official position of the Centers for Disease Control and Prevention. Use of trade
324 names is for identification only and does not imply endorsement by the Centers for Disease
325 Control and Prevention.

326

327 Footnotes

328 ¹ See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a;
329 44 U.S.C. §3501 et seq.

330 References

- 331 1. Botti-Lodovico Y, Rosenberg E, Sabeti PC. Testing in a Pandemic - Improving Access,
332 Coordination, and Prioritization. *N Engl J Med* **2021**; 384:197–199.
- 333 2. Mak GC, Cheng PK, Lau SS, et al. Evaluation of rapid antigen test for detection of SARS-
334 CoV-2 virus. *J Clin Virol* **2020**; 129:104500.
- 335 3. Toptan T, Eckermann L, Pfeiffer AE, et al. Evaluation of a SARS-CoV-2 rapid antigen test:
336 Potential to help reduce community spread? *J Clin Virol* **2020**; 135:104713.
- 337 4. Porte L, Legarraga P, Vollrath V, et al. Evaluation of a novel antigen-based rapid detection
338 test for the diagnosis of SARS-CoV-2 in respiratory samples. *Int J Infect Dis* **2020**; 99:328–
339 333.
- 340 5. Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW Rapid
341 Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima
342 County, Arizona, November 3-17, 2020. *MMWR Morb Mortal Wkly Rep* **2021**; 70:100–105.
- 343 6. Redditt V, Wright V, Rashid M, Male R, Bogoch I. Outbreak of SARS-CoV-2 infection at a
344 large refugee shelter in Toronto, April 2020: a clinical and epidemiologic descriptive

- 345 analysis. *CMAJ Open* **2020**; 8:E819–E824.
- 346 7. Patel MC, Chaisson LH, Borgetti S, et al. Asymptomatic SARS-CoV-2 Infection and
347 COVID-19 Mortality During an Outbreak Investigation in a Skilled Nursing Facility. *Clin*
348 *Infect Dis* **2020**; 71:2920–2926.
- 349 8. Ghinai I, Woods S, Ritger KA, et al. Community Transmission of SARS-CoV-2 at Two
350 Family Gatherings - Chicago, Illinois, February-March 2020. *MMWR Morb Mortal Wkly Rep*
351 **2020**; 69:446–450.
- 352 9. Quidel Sofia SARS Antigen Test Emergency Use Authorization. Available at:
353 <https://www.fda.gov/media/137885/download>. Accessed 31 January 2021.
- 354 10. Arnaout R, Lee RA, Lee GR, et al. SARS-CoV2 Testing: The Limit of Detection Matters.
355 *bioRxiv* **2020**; Available at: <http://dx.doi.org/10.1101/2020.06.02.131144>.
- 356 11. Young S, Taylor SN, Cammarata CL, et al. Clinical Evaluation of BD Veritor SARS-CoV-2
357 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2
358 SARS Antigen Point-of-Care Test. *J Clin Microbiol* **2020**; 59. Available at:
359 <http://dx.doi.org/10.1128/JCM.02338-20>.
- 360 12. Kremer R. CDC: UW Antigen Tests Missed Nearly 59 Percent Of COVID-19 Cases Among
361 Asymptomatic Individuals. 2021. Available at: [https://www.wpr.org/cdc-uw-antigen-tests-](https://www.wpr.org/cdc-uw-antigen-tests-missed-nearly-59-percent-covid-19-cases-among-asymptomatic-individuals)
362 [missed-nearly-59-percent-covid-19-cases-among-asymptomatic-individuals](https://www.wpr.org/cdc-uw-antigen-tests-missed-nearly-59-percent-covid-19-cases-among-asymptomatic-individuals). Accessed 31
363 January 2021.
- 364 13. Pray IW, Ford L, Cole D, et al. Performance of an Antigen-Based Test for Asymptomatic
365 and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin,

- 366 September-October 2020. *MMWR Morb Mortal Wkly Rep* **2021**; 69:1642–1647.
- 367 14. Harapan H, Anwar S, Nainu F, et al. Perceived Risk of Being Infected With SARS-CoV-2: A
368 Perspective From Indonesia. *Disaster Med Public Health Prep* **2020**; :1–5.
- 369 15. Quick J. nCoV-2019 sequencing protocol. **2020**; Available at:
370 <https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmui6w.pdf>. Accessed 31
371 January 2021.
- 372 16. Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR method for MinION and Illumina
373 sequencing of Zika and other virus genomes directly from clinical samples. *Nat Protoc*
374 **2017**; 12:1261–1276.
- 375 17. artic-network. [artic-network/artic-ncov2019](https://github.com/artic-network/artic-ncov2019). Available at: [https://github.com/artic-](https://github.com/artic-network/artic-ncov2019)
376 [network/artic-ncov2019](https://github.com/artic-network/artic-ncov2019). Accessed 31 January 2021.
- 377 18. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution.
378 *Bioinformatics* **2018**; 34:4121–4123.
- 379 19. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis.
380 *Virus Evol* **2018**; 4:vex042.
- 381 20. Popa A, Genger J-W, Nicholson MD, et al. Genomic epidemiology of superspreading
382 events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2.
383 *Sci Transl Med* **2020**; 12. Available at: <http://dx.doi.org/10.1126/scitranslmed.abe2555>.
- 384 21. Moreno GK, Braun KM, Riemersma KK, et al. Revealing fine-scale spatiotemporal
385 differences in SARS-CoV-2 introduction and spread. *Nat Commun* **2020**; 11:5558.
- 386 22. Braun KM, Moreno GK, Halfmann PJ, et al. Transmission of SARS-CoV-2 in domestic cats

387 imposes a narrow bottleneck. bioRxiv **2020**; Available at:

388 <http://dx.doi.org/10.1101/2020.11.16.384917>.

389 23. Pray IW, Kocharian A, Mason J, Westergaard R, Meiman J. Trends in Outbreak-Associated
390 Cases of COVID-19 - Wisconsin, March-November 2020. MMWR Morb Mortal Wkly Rep
391 **2021**; 70:114–117.


392 24. Mack CD, Wasserman EB, Perrine CG, et al. Implementation and Evolution of Mitigation
393 Measures, Testing, and Contact Tracing in the National Football League, August 9-
394 November 21, 2020. MMWR Morb Mortal Wkly Rep **2021**; 70:130–135.

395 25. Honein MA, Christie A, Rose DA, et al. Summary of Guidance for Public Health Strategies
396 to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths,
397 December 2020. MMWR Morb Mortal Wkly Rep **2020**; 69:1860–1867.

398 30. Atherstone C, Siegel M, Schmitt-Matzen E, et al. SARS-CoV-2 Transmission Associated
399 with High School Wrestling Tournaments — Florida, December 2020–January 2021.
400 MMWR Morb Mortal Wkly Rep 2021;70:141–143.

401

402 Figures




403


404 **Figure 1.** Graphical abstract of cryptic transmission that could occur when a person is asymptomatic and
405 the amount of virus remains below the limit of detection for antigen tests despite the person being
406 potentially infectious to others. This is a schematic and is meant to represent general, not quantitative,
407 relationships among these variables. LOD = limit of detection.

408

A




B



409
 410 **Figure 2. Overview of Outbreak 1** A) Epidemic curve for confirmed COVID-19 cases (n = 32) among
 411 students and staff associated with the athletics program during Outbreak 1. Abbreviations: Ag = antigen;
 412 COVID-19 = coronavirus disease 2019; RT-PCR = reverse transcription–polymerase chain reaction. B)
 413 Graphical representation of known interactions between all persons in the athletics program affected by
 414 Outbreak 1. Roommates are shown by a solid black line; confirmed close contact with a positive case as

415 identified through contact tracing interviews is shown with a red line; r persons who attended indoor team
416 meetings together while following physical distancing policies (> 6 feet apart and wearing masks) are
417 shown with a dashed gray line; persons who received false negative antigen results are shown with a red
418 circle.
419



420

421 **Figure 3. Phylogeny of Outbreak 1.** A) Time-resolved phylogenetic tree created using Nextstrain tools
422 and nomenclature showing the team sequences contextualized with all available community sequences
423 (gray) for 25 (78%) of 32 confirmed cases associated with Outbreak 1; tips affiliated with Outbreak 1 are
424 colored red. B) Zoomed in time-resolved phylogeny showing all of these samples are part of the same

425 athletics cluster. C) Divergence tree showing the number of mutations each sequence has relative to
426 Wuhan/WH01/2019 (Genbank: MN908947.3), a standard reference comparison sequence.

427

428

429

430

431

432

433

434

435

436

437

438

439

440


441

442

443

444

445




446

447 **Figure 4. Overview of Outbreak 2.** A) Epidemic curve for Outbreak 2 showing confirmed (n = 12)

448 COVID-19 cases within the two intercollegiate teams. Testing was not conducted on day-2.

449

450



451
452 **Figure 5. Phylogeny of Outbreak 2.** A) Time-resolved phylogenetic tree created using Nextstrain tools
453 and nomenclature showing 8 (67%) of 12 available samples from Outbreak 2 sequences contextualized
454 with all available community sequences (light gray). Tips affiliated with Team 1 are colored red, and Team
455 2's sequences are colored dark gray. B) Zoomed in time-resolved phylogeny showing all these samples
456 are part of the same athletics cluster. C) Divergence tree showing the number of mutations each

457 sequence has relative to Wuhan/WH01/2019 (Genbank: MN908947.3), a standard reference comparison

458 sequence.

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475 **Table 1. Characteristics and exposure details for confirmed COVID-19 cases (n=32) during**
476 **Outbreak 1.**
477

Characteristics	No. (%)
Confirmed cases of COVID-19 associated with Outbreak 1	N=32
Program affiliation	
Student-athlete	22 (69%)
Staff	10 (31%)
Symptomatic	27 (84%)
Possible contact with a confirmed COVID-19 case during exposure period	
Housemate	6 (19%)
Team meeting	13 (40%)
Social gathering (outside of program)	3 (9%)
Other	2 (6%)
No known exposure	8 (25%)
Source of positive RT-PCR result	
Symptom-based testing (RT-PCR only)	4 (13%)
Antigen-based screening with confirmatory RT-PCR	7 (22%)
Mass combined testing (paired RT-PCR and antigen testing)	21 (66%)
Antigen-positive	3 (14%)
Antigen-negative	18 (86%)

478

479